Human RCTPubMed ID: 38517291·2024

Effects of Retatrutide on Body Composition: MRI-based Analysis of Fat Distribution

Samson SL, Velasquez MA, Darcourt J, et al.

Obesity, 2024 · n = 187

Key finding

Retatrutide preferentially reduced visceral fat (34% reduction at 15mg) versus subcutaneous fat (19% reduction), with minimal muscle loss despite 22% total weight reduction.

Summary

Mechanistic substudy using MRI to characterize changes in visceral fat, subcutaneous fat, and muscle mass with retatrutide versus placebo.

Read the study

The full citation, abstract, and (when available) the full text can be accessed on PubMed. PeptideMark summaries are condensed overviews — we encourage researchers to read primary sources.

View on PubMed

Related compound

RetatrutideL4

A triple-acting GIP/GLP-1/glucagon receptor agonist in Phase 3 trials showing potentially the highest weight loss of any drug in development.

More research on Retatrutide

TRIUMPH-NAS: Retatrutide for Non-Alcoholic Steatohepatitis

Journal of Hepatology · 2025 · Human RCT

TRIUMPH-OA: Retatrutide for Obesity-Related Osteoarthritis

Osteoarthritis and Cartilage · 2025 · Human RCT

Genetic Polymorphisms Predict Retatrutide Response: GWAS Analysis

Cell Metabolism · 2025 · Human RCT

Comparative Efficacy: Retatrutide vs Tirzepatide in Randomized Head-to-Head Trial

New England Journal of Medicine · 2025 · Human RCT

TRIUMPH 1: Retatrutide versus Placebo in Obesity (Phase 3)

Lancet Diabetes & Endocrinology · 2024 · Human RCT